Matrix metalloproteinase 1 (MMP-1) is an activator of protease-activated receptor 1 (PAR-1), which is known to mediate the release of endothelin 1 (ET-1) in endothelial cells and activate the RhoA kinase (ROCK) pathway. Recently, we reported increased serum and vascular MMP-1 in women with preeclampsia and hypothesized that the action of MMP-1 on PAR-1 might have vasoconstrictive effects. Resistance-sized omental arteries obtained from normal pregnant women were mounted on a myograph system and perfused with MMP-1 in a dose range of 0.025 to 25 ng/mL or with angiotensin II (Ang II) in a dose range of 0.001 to 10 µmol/L in the presence of intraluminal MMP-1 (2.5 ng/mL) perfusion. Angiotensin II dose response was also performed with omental arteries from women with preeclampsia. Matrix metalloproteinase 1 caused dose-dependent vasoconstriction in endothelium-intact, but not in endothelium-denuded, vessels from normal pregnant women, which was blocked by inhibitors of PAR-1 and ET-1 type A receptor blocker. Intraluminal perfusion with a constant amount of MMP-1 enhanced vessel reactivity to Ang II, which was blocked by inhibitors of PAR-1, ROCK, and ET-1. Enhanced vascular reactivity to Ang II was observed in endothelium-intact, but not in endothelium-denuded, arteries of women with preeclampsia. Inhibitors of PAR-1, ROCK, and ET-1 blocked enhanced vascular reactivity to Ang II in endothelium-intact preeclamptic arteries. These data demonstrate that MMP-1 has potent vasoconstrictor effects and the ability to enhance vascular reactivity to vasoconstrictor hormones, which are mediated by an endothelial PAR-1, ROCK, and ET-1 pathway. Increased circulating levels of MMP-1 and its increased expression in systemic vessels of women with preeclampsia may contribute to the development of maternal hypertension.
AbalosECuestaCGrossoALChouDSayL. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2013;170(1):1–7.
HuppertzBWeissGMoserG. Trophoblast invasion and oxygenation of the placenta: measurements versus presumptions. J Reprod Immunol. 2014;101-102:74–79.
4.
HubelCA. Oxidative stress in the pathogenesis of preeclampsia. Proc Soc Exp Biol Med. 1999;222(3):222–235.
5.
WalshSW. Maternal-placental interactions of oxidative stress and antioxidants in preeclampsia. Semin Reprod Endocrinol. 1998;16(1):93–104.
6.
WalshSWVaughanJEWangYRobertsLJ II. Placental isoprostane is significantly increased in preeclampsia. FASEB J. 2000;14(10):1289–1296.
7.
ClarkPBoswellFGreerIA. The neutrophil and preeclampsia. Semin Reprod Endocrinol. 1998;16(1):57–64.
8.
GervasiMTChaiworapongsaTPacoraP. Phenotypic and metabolic characteristics of monocytes and granulocytes in preeclampsia. Am J Obstet Gynecol. 2001;185(4):792–797.
SacksGPStudenaKSargentKRedmanCW. Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis. Am J Obstet Gynecol. 1998;179(1):80–86.
11.
LeikCEWalshSW. Neutrophils infiltrate resistance-sized vessels of subcutaneous fat in women with preeclampsia. Hypertension. 2004;44(1):72–77.
12.
CaddenKAWalshSW. Neutrophils, but not lymphocytes or monocytes, infiltrate maternal systemic vasculature in women with preeclampsia. Hypertens Pregnancy. 2008;27(4):396–405.
13.
RobertsJMTaylorRNMusciTJRodgersGMHubelCAMcLaughlinMK. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol. 1989;161(5):1200–1204.
14.
TaylorRNde GrootCJChoYKLimKH. Circulating factors as markers and mediators of endothelial cell dysfunction in preeclampsia. Semin Reprod Endocrinol. 1998;16(1):17–31.
15.
ShahTJWalshSW. Activation of NF-kappaB and expression of COX-2 in association with neutrophil infiltration in systemic vascular tissue of women with preeclampsia. Am J Obstet Gynecol. 2007;196(1):48. e1–e8.
16.
PeiD. Matrix metalloproteinases target protease-activated receptors on the tumor cell surface. Cancer Cell. 2005;7(3):207–208.
17.
BoireACovicLAgarwalAJacquesSSherifiSKuliopulosA. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell. 2005;120(3):303–313.
18.
AhnHSChackalamannilSBoykowGGrazianoMPFosterC. Development of proteinase-activated receptor 1 antagonists as therapeutic agents for thrombosis, restenosis and inflammatory diseases. Curr Pharm Des. 2003;9(28):2349–2365.
19.
TrivediVBoireATchernychevB. Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site. Cell. 2009;137(2):332–343.
20.
HanemaaijerRKoolwijkPle ClercqLde VreeWJvan HinsberghVW. Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. Effects of tumour necrosis factor alpha, interleukin 1 and phorbol ester. Biochem J. 1993;296(pt 3):803–809.
21.
GrabDJNyarkoEBaratNCNikolskaiaOVDumlerJS. Anaplasma phagocytophilum-Borrelia burgdorferi coinfection enhances chemokine, cytokine, and matrix metalloprotease expression by human brain microvascular endothelial cells. Clin Vaccine Immunol. 2007;14(11):1420–1424.
22.
ZhuYHojoYIkedaUTakahashiMShimadaK. Interaction between monocytes and vascular smooth muscle cells enhances matrix metalloproteinase-1 production. J Cardiovasc Pharmacol. 2000;36(2):152–161.
23.
NagaseHVisseRMurphyG. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69(3):562–573.
24.
NagaseHSuzukiKEnghildJJSalvesenG. Stepwise activation mechanisms of the precursors of matrix metalloproteinases 1 (tissue collagenase) and 3 (stromelysin). Biomed Biochim Acta. 1991;50(4-6):749–754.
25.
Estrada-GutierrezGCappelloREMishraN. Increased expression of matrix metalloproteinase-1 in systemic vessels of preeclamptic women: a critical mediator of vascular dysfunction. Am J Pathol. 2011;178(1):451–460.
26.
CoughlinSR. Protease-activated receptors in vascular biology. Thromb Haemost. 2001;86(1):298–307.
27.
EtoMBarandierCRathgebL. Thrombin suppresses endothelial nitric oxide synthase and upregulates endothelin-converting enzyme-1 expression by distinct pathways: role of Rho/ROCK and mitogen-activated protein kinase. Circ Res. 2001;89(7):583–590.
28.
SchiniVBVanhouttePM. Endothelin-1: a potent vasoactive peptide. Pharmacol Toxicol. 1991;69(5):303–309.
29.
BuhlAMJohnsonNLDhanasekaranNJohnsonGL. G alpha 12 and G alpha 13 stimulate Rho-dependent stress fiber formation and focal adhesion assembly. J Biol Chem. 1995;270(42):24631–24634.
30.
CoughlinSR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost. 2005;3(8):1800–1814.
31.
MishraNNugentWHMahavadiSWalshSW. Mechanisms of enhanced vascular reactivity in preeclampsia. Hypertension. 2011;58(5):867–873.
32.
CaoXLuoTLuoXTangZ. Resveratrol prevents AngII-induced hypertension via AMPK activation and RhoA/ROCK suppression in mice. Hypertens Res. 2014;37(9):803–810.
33.
AbramovichDRPageKRWrightF. Effect of angiotensin II and 5-hydroxytryptamine on the vessels of the human foetal cotyledon. Br J Pharmacol. 1983;79(1):53–56.
34.
MaigaardSFormanAAnderssonKE. Differential effects of angiotensin, vasopressin and oxytocin on various smooth muscle tissues within the human uteroplacental unit. Acta Physiol Scand. 1986;128(1):23–31.
35.
MakKKGudeNMWaltersWABouraAL. Effects of vasoactive autacoids on the human umbilical-fetal placental vasculature. Br J Obstet Gynaecol. 1984;91(2):99–106.
36.
TulenkoTN. The actions of prostaglandins and cyclo-oxygenase inhibition on the resistance vessels supplying the human fetal placenta. Prostaglandins. 1981;21(6):1033–1043.
37.
AalkjaerCDanielsenHJohannesenPPedersenEBRasmussenAMulvanyMJ. Abnormal vascular function and morphology in pre-eclampsia: a study of isolated resistance vessels. Clin Sci (Lond). 1985;69(4):477–482.
38.
NarumiyaHZhangYFernandez-PatronCGuilbertLJDavidgeST. Matrix metalloproteinase-2 is elevated in the plasma of women with preeclampsia. Hypertens Pregnancy. 2001;20(2):185–194.
39.
Fernandez-PatronCRadomskiMWDavidgeST. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res. 1999;85(10):906–911.
40.
AbdalvandAMortonJSBourqueSLQuonALDavidgeST. Matrix metalloproteinase enhances big-endothelin-1 constriction in mesenteric vessels of pregnant rats with reduced uterine blood flow. Hypertension. 2013;61(2):488–493.
UrataHBoehmKDPhilipA. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest. 1993;91(4):1269–1281.
43.
van MourikJARomani de WitTVoorbergJ. Biogenesis and exocytosis of Weibel-Palade bodies. Histochem Cell Biol. 2002;117(2):113–122.
44.
MarsenTASimonsonMSDunnMJ. Thrombin induces the preproendothelin-1 gene in endothelial cells by a protein tyrosine kinase-linked mechanism. Circ Res. 1995;76(6):987–995.
45.
GreerIALeaskRHodsonBADawesJKilpatrickDCListonWA. Endothelin, elastase, and endothelial dysfunction in pre-eclampsia. Lancet. 1991;337(8740):558.
46.
TaylorRNVarmaMTengNNRobertsJM. Women with preeclampsia have higher plasma endothelin levels than women with normal pregnancies. J Clin Endocrinol Metab. 1990;71(6):1675–1677.
47.
MousaAACappelloREEstrada-GutierrezG. Preeclampsia is associated with alterations in DNA methylation of genes involved in collagen metabolism. Am J Pathol. 2012;181(4):1455–1463.
48.
ShuklaJWalshSW. Neutrophil release of myeloperoxidase in systemic vasculature of obese women may put them at risk for preeclampsia. Reprod Sci. 2015;22(3):300–307.
49.
GantNFDaleyGLChandSWhalleyPJMacDonaldPC. A study of angiotensin II pressor response throughout primigravid pregnancy. J Clin Invest. 1973;52(11):2682–2689.
50.
PooleRMElkinsonS. Vorapaxar: first global approval. Drugs. 2014;74(10):1153–1163.
51.
LohnMPlettenburgOKanntA. End-organ protection in hypertension by the novel and selective Rho-kinase inhibitor, SAR407899. World J Cardiol. 2015;7(1):31–42.
52.
FukumotoYYamadaNMatsubaraH. Double-blind, placebo-controlled clinical trial with a rho-kinase inhibitor in pulmonary arterial hypertension. Circ J. 2013;77(10):2619–2625.
53.
LeeYHSongGG. Meta-analysis of randomized controlled trials of bosentan for treatment of pulmonary arterial hypertension. Korean J Intern Med. 2013;28(6):701–707.
54.
HuJVan den SteenPESangQXOpdenakkerG. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov. 2007;6(6):480–498.
